GOLDEN BIOTECHNOLOGY CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.5 TWD | -0.81% |
|
-2.39% | -37.58% |
| Sales 2022 | 218M 6.71M | Sales 2023 | 63.43M 1.95M | Capitalization | 5.58B 172M |
|---|---|---|---|---|---|
| Net income 2022 | -272M -8.38M | Net income 2023 | -362M -11.15M | EV / Sales 2022 | 38.1 x |
| Net cash position 2022 | 239M 7.36M | Net Debt 2023 | 61.04M 1.88M | EV / Sales 2023 | 89 x |
| P/E ratio 2022 |
-31.4
x | P/E ratio 2023 |
-15.4
x | Employees | 122 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.81% | ||
| 1 week | -2.39% | ||
| 1 month | -14.63% | ||
| 3 months | -38.90% | ||
| 6 months | -37.42% | ||
| Current year | -37.58% |
1 week
24.05
25.90
1 month
24.0030.15
Current year
24.0043.85
1 year
24.0060.40
3 years
24.00335.00
5 years
24.00335.00
10 years
23.66335.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ching Tien Su
CEO | Chief Executive Officer | - | 19-03-03 |
Li Yue Wu
FOU | Founder | - | 02-09-26 |
Mu Tseng Tseng
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sheng Yung Liu
FOU | Founder | - | 02-09-26 |
Li Yue Wu
FOU | Founder | - | 02-09-26 |
Yue Chun Chen
BRD | Director/Board Member | - | 09-06-25 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 112 M€ | +4.61% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 24.5 | -0.81% | 381,841 |
| 24-05-30 | 24.7 | -1.59% | 269,222 |
| 24-05-29 | 25.1 | +2.66% | 513,931 |
| 24-05-28 | 24.45 | -1.01% | 328,494 |
| 24-05-27 | 24.7 | -1.59% | 430,608 |
End-of-day quote Taipei Exchange, May 30, 2024
More quotes
Golden Biotechnology Corp is a Taiwan-based company mainly engaged in the development of new anti-cancer drugs. The Company's main development projects are novel compounds of Antroquinonol for the treatment of non-small cell lung cancer, acute myeloid leukemia, pancreatic cancer, hyperlipidemia, hepatitis B, and Corona Virus Disease 2019 (Covid-19), which are broadly effective small molecule drugs with no systemic toxicity. The Company is also engaged in the manufacture and sales of health foods and dietary supplements. The main products include antrodia camphorata mycelium capsules and others. The Company sells products in the Taiwan market as well as in other areas of Asia.
| 1st Jan change | Capi. | |
|---|---|---|
| -37.58% | 107M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- 4132 Stock
